Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Black Diamond Therapeutics (BDTX) Drops -33% Over 30 Days as Phase 3 Timeline Shifts

Black Diamond Therapeutics (BDTX) Drops -33% Over 30 Days as Phase 3 Timeline Shifts

Key Takeaways

  • Black Diamond Therapeutics (BDTX), a clinical-stage oncology company developing the brain-penetrant EGFR inhibitor silevertinib, has declined roughly 33% over the trailing 30 days, from about $2.08 to near $1.39.
  • The pullback extends a longer slide: shares are down roughly 35% over the trailing three months and about 64% over the past 52 weeks.
  • Updated Phase 2 data — including a 60% objective response rate (ORR) and an 86% central nervous system (CNS) response rate — was positive but failed to stem selling as investors focused on a Phase 3 start pushed to the second quarter of 2027 and future financing needs.
  • The company posted a $10.0 million net loss for the third quarter of 2026 and ended the period with roughly $102.0 million in cash, cash equivalents, and investments, which it expects to fund operations into the second half of 2028.
  • As a single pre-revenue security with a beta near 3.5 and elevated short interest, BDTX represents concentrated, high-volatility exposure rather than diversified fund exposure.
  • For additional context on this ticker, explore its Price Targets and Forecast pages.
  • To discover algorithmic trading ideas across the market, explore Trending AI Robots.

Black Diamond Therapeutics and Its Focused Pipeline

BDTX is the Nasdaq-listed common stock of Black Diamond Therapeutics, Inc., a clinical-stage oncology company headquartered in Cambridge, Massachusetts. Rather than a diversified fund, it is a single micro-cap security with a market capitalization of roughly $80 million and approximately 57 million shares outstanding. The company's "MasterKey" platform targets families of oncogenic mutations, with the goal of building therapies that are brain-penetrant, overcome resistance, and minimize off-target toxicities.

The lead asset is silevertinib (BDTX-1535), an oral, brain-penetrant, fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets the epidermal growth factor receptor (EGFR). It is in Phase 2 development for frontline non-small cell lung cancer (NSCLC) with EGFR non-classical mutations and in a randomized Phase 2 trial for newly diagnosed glioblastoma (GBM). Earlier-stage programs include BDTX-4933, a RAF MasterKey inhibitor out-licensed to Servier, and BDTX-4876, a selective FGFR2/3 candidate. Because the company has no approved products or recurring revenue, its equity value is driven almost entirely by clinical data, regulatory milestones, and balance-sheet strength — a concentrated structure that amplifies both upside and downside volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Price Action: The 30-Day Decline and Three-Month Trend

Over the trailing 30 days, BDTX has fallen roughly 33%, sliding from about $2.08 in mid-October to a most recent close near $1.39, with intraday trading briefly pressing toward the low $1.30s. The move has been decisively trend-driven and punctuated by sharp single-day declines rather than a gradual grind, consistent with the stock's elevated beta — a measure of volatility relative to the broader market — of approximately 3.5.

The three-month picture is similarly weak. From a late-August level near $2.15, shares have declined roughly 35%, and from their late-summer peak in the low-to-mid $2.20s the drawdown is larger still. The prevailing pattern has been one of lower highs and lower lows, with rallies in late October failing near the $2.08 area before giving way to renewed selling pressure.

Key Catalysts Behind the Latest Move

The sharpest catalyst came on November 10, when the company reported updated Phase 2 silevertinib data alongside third-quarter results and U.S. Food and Drug Administration (FDA) feedback supporting a registrational program. The data — a 60% ORR, a 93% disease control rate, a 15.0-month median progression-free survival (PFS), and an 86% CNS objective response rate in patients with untreated brain metastases — was clinically encouraging. Yet the stock fell roughly 14% that session in a classic "sell the news" reaction, as much of the efficacy signal had already been telegraphed at the 2026 ASCO annual meeting.

Investors instead focused on the timeline and capital requirements. The pivotal Phase 3 trial is now expected to begin in the second quarter of 2027, with preliminary data not anticipated until 2028, leaving a limited near-term catalyst path. Management has also indicated that additional capital will be required to fund the program through key readouts, introducing a dilution overhang that weighed on sentiment. These concerns were compounded earlier in the month by an analyst downgrade citing delayed trial results, as well as elevated short interest of roughly 9% of shares outstanding and broader risk-aversion across small-cap biotechnology.

Broader Context for the Quarterly Pullback

The three-month decline reflects a combination of fading post-data momentum, financing risk, and a challenging backdrop for pre-revenue biotech. After the initial ASCO data release, the stock traded up into the mid-$2.20s in late August before distribution set in. A lack of near-term catalysts, the extension of the Phase 3 start into 2027, and persistent concerns about future equity issuance gradually eroded the risk premium.

Institutional positioning was mixed: notable holders added shares in the second quarter of 2026, while others trimmed or exited positions. This divergence, together with a 52-week decline of roughly 64% and high beta, indicates that BDTX has been treated as a higher-risk, catalyst-dependent holding rather than a stable core position. The macro environment — characterized by elevated interest rates that raise the discount rate on distant, unproven cash flows — has added further pressure on speculative biotech valuations.

Looking Ahead at Key Milestones

Going forward, the most important variable is execution on the silevertinib pivotal program. Key milestones include the completion of Cohort 4 safety data required before the Phase 3 trial can open, the anticipated second-quarter-2027 initiation, and eventual readouts on CNS objective response rate and PFS. Any shift in these timelines — in either direction — is likely to move the shares materially.

Financing is a second critical factor. With roughly $102 million in cash and a runway into the second half of 2028, the company has flexibility, but funding the Phase 3 program through key readouts will likely require additional capital, and the terms and timing of any offering will matter for existing shareholders. Investors should also monitor the GBM program, where interim PFS data are expected in the first half of 2028, and the broader environment for small-cap biotech, including interest-rate expectations, risk appetite, and sector-wide capital flows. As with all clinical-stage oncology companies, the risks of trial failure, regulatory setbacks, and share dilution remain significant and should be weighed against the potential catalysts ahead.

My Workflow With Tickeron’s AI Screener

When analyzing names like this, I turn to Tickeron’s AI Screener to quickly compare volatility metrics, industry patterns, and signal history against peers. It helps place a single stock’s risk profile in context without replacing my own due diligence on clinical timelines and balance-sheet runway. The tool surfaces ideas efficiently and lets me customize screens to match the factors I watch most closely.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BDTX

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


BDTX sees MACD Histogram crosses below signal line

BDTX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 38 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 59 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BDTX entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +12.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDTX advanced for three days, in 199 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

BDTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (3.596). P/E Ratio (-2.313) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.

Industry Biotechnology

Industry
N/A
Address
245 First Street
Phone
+1 617 252-0848
Employees
21
Web
https://www.blackdiamondtherapeutics.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.